Helen Tayton-Martin
2016
In 2016, Helen Tayton-Martin earned a total compensation of $1.1M as Chief Business Officer at Adaptimmune Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $80,963 |
|---|---|
| Option Awards | $674,104 |
| Salary | $299,865 |
| Other | $16,424 |
| Total | $1,071,356 |
Tayton-Martin received $674.1K in option awards, accounting for 63% of the total pay in 2016.
Tayton-Martin also received $81K in non-equity incentive plan, $299.9K in salary and $16.4K in other compensation.
Rankings
In 2016, Helen Tayton-Martin's compensation ranked 7,910th out of 14,075 executives tracked by ExecPay. In other words, Tayton-Martin earned more than 43.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,910 out of 14,075 | 44th |
Division Manufacturing | 3,009 out of 5,489 | 45th |
Major group Chemicals And Allied Products | 999 out of 1,895 | 47th |
Industry group Drugs | 774 out of 1,538 | 50th |
Industry Biological Products, Except Diagnostic Substances | 137 out of 279 | 51st |
Source: SEC filing on March 15, 2019.
Tayton-Martin's colleagues
We found three more compensation records of executives who worked with Helen Tayton-Martin at Adaptimmune Therapeutics in 2016.